• Publications
  • Influence
Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness
Fexinidazole is shown to be a short-course, safe and effective oral treatment curing both acute and chronic HAT and that could be implemented at the primary health care level and the results of the preclinical pharmacological and safety studies indicate that fexinidrazole is a safe andeffective oral drug candidate with no untoward effects that would preclude evaluation in man.
The GreenScreen genotoxicity assay: a screening validation programme.
A yeast (Saccharomyces cerevisiae) DNA repair reporter assay termed the GreenScreen assay (GSA) is described, developed to provide a pre-regulatory screening assay for use by the pharmaceutical industry and in other applications where significant numbers of compounds need to be tested.
Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept®, Roche): overview
Animal studies suggested that patients who took nelfinavir mesylate with elevated levels of EMS are at no increased risk for carcinogenicity or teratogenicity over their background risk, since mutations are prerequisites for such downstream events.
A differential killing assay for mutagens and carcinogens based on an improved repair-deficient strain of Escherichia coli.
A uvrA recA lexA triple mutant CM871 that combines extreme repair deficiency with near wild-type growth is constructed that is used in conjunction with an isogenic strain WP67 uvr a polA and isogenic wild- type strain WP2 in a differential killing test.